Evolutionary Action Score of <i>TP53</i> Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

David M. Neskey(MUSC Hollings Cancer Center), Abdullah A. Osman(The University of Texas MD Anderson Cancer Center), Thomas J. Ow(Albert Einstein College of Medicine), Panagiotis Katsonis(Baylor Genetics), Thomas O. McDonald(Rice University), Stephanie C. Hicks(Dana-Farber Cancer Institute), Teng‐Kuei Hsu(Baylor Genetics), Curtis R. Pickering(The University of Texas MD Anderson Cancer Center), Alexandra M. Ward(The University of Texas MD Anderson Cancer Center), Ameeta A. Patel(The University of Texas MD Anderson Cancer Center), John S. Yordy(Southwestern Medical Center), Heath D. Skinner(The University of Texas MD Anderson Cancer Center), Uma Giri(The University of Texas MD Anderson Cancer Center), Daisuke Sano(Nagahama Institute of Bio-Science and Technology), Michael D. Story(Southwestern Medical Center), Beth M. Beadle(The University of Texas MD Anderson Cancer Center), Adel K. El‐Naggar(The University of Texas MD Anderson Cancer Center), Merrill S. Kies(The University of Texas MD Anderson Cancer Center), William Nassib William(The University of Texas MD Anderson Cancer Center), Carlos Caulı́n(The University of Texas MD Anderson Cancer Center), Mitchell J. Frederick(The University of Texas MD Anderson Cancer Center), Marek Kimmel(Rice University), Jeffrey N. Myers(The University of Texas MD Anderson Cancer Center), Olivier Lichtarge(Baylor Genetics)
Cancer Research
January 29, 2015
Cited by 159Open Access
Full Text

Abstract

Abstract TP53 is the most frequently altered gene in head and neck squamous cell carcinoma, with mutations occurring in over two-thirds of cases, but the prognostic significance of these mutations remains elusive. In the current study, we evaluated a novel computational approach termed evolutionary action (EAp53) to stratify patients with tumors harboring TP53 mutations as high or low risk, and validated this system in both in vivo and in vitro models. Patients with high-risk TP53 mutations had the poorest survival outcomes and the shortest time to the development of distant metastases. Tumor cells expressing high-risk TP53 mutations were more invasive and tumorigenic and they exhibited a higher incidence of lung metastases. We also documented an association between the presence of high-risk mutations and decreased expression of TP53 target genes, highlighting key cellular pathways that are likely to be dysregulated by this subset of p53 mutations that confer particularly aggressive tumor behavior. Overall, our work validated EAp53 as a novel computational tool that may be useful in clinical prognosis of tumors harboring p53 mutations. Cancer Res; 75(7); 1527–36. ©2015 AACR.


Related Papers

No related papers found

Powered by citation graph analysis